These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 21544528)
1. Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (Rituximab®) for patients with non-Hodkin's Lymphoma: results of a prospective phase I/II study. Haidenberger A; Fromm-Haidenberger S; de Vries A; Popper BA; Steurer M; Skvortsova I; Kantner J; Gunsilius E; Lukas P Strahlenther Onkol; 2011 May; 187(5):300-5. PubMed ID: 21544528 [TBL] [Abstract][Full Text] [Related]
2. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
4. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469 [TBL] [Abstract][Full Text] [Related]
5. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049 [TBL] [Abstract][Full Text] [Related]
6. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. Witzens-Harig M; Hensel M; Unterhalt M; Herfarth K BMC Cancer; 2011 Feb; 11():87. PubMed ID: 21352561 [TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. Kaya H; Keung YK; Case D; Cruz JM; Perry JJ; Radford JE; Hurd DD Biol Blood Marrow Transplant; 2002; 8(10):544-9. PubMed ID: 12434949 [TBL] [Abstract][Full Text] [Related]
9. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Rapoport AP; Meisenberg B; Sarkodee-Adoo C; Fassas A; Frankel SR; Mookerjee B; Takebe N; Fenton R; Heyman M; Badros A; Kennedy A; Jacobs M; Hudes R; Ruehle K; Smith R; Kight L; Chambers S; MacFadden M; Cottler-Fox M; Chen T; Phillips G; Tricot G Bone Marrow Transplant; 2002 Feb; 29(4):303-12. PubMed ID: 11896427 [TBL] [Abstract][Full Text] [Related]
10. New developments in immunotherapy for non-Hodgkin's lymphoma. Leonard JP; Furman RR; Ruan J; Coleman M Curr Oncol Rep; 2005 Sep; 7(5):364-71. PubMed ID: 16091197 [TBL] [Abstract][Full Text] [Related]
11. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W Ann Hematol; 2000 Sep; 79(9):493-500. PubMed ID: 11043420 [TBL] [Abstract][Full Text] [Related]
12. 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience. Gmeiner Stopar T; Fettich J; Zver S; Mlinaric-Rascan I; Hojker S; Socan A; Peitl PK; Mather S Nucl Med Commun; 2008 Dec; 29(12):1059-65. PubMed ID: 18987526 [TBL] [Abstract][Full Text] [Related]
13. [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012 [TBL] [Abstract][Full Text] [Related]
14. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy. Picardi M; Zeppa P; Ciancia G; Pettinato G; Grimaldi F; Fabbricini R; Mainolfi C; Pane F Leuk Lymphoma; 2011 Nov; 52(11):2082-9. PubMed ID: 21663508 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994 [TBL] [Abstract][Full Text] [Related]
17. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Cvetković RS; Perry CM Drugs; 2006; 66(6):791-820. PubMed ID: 16706552 [TBL] [Abstract][Full Text] [Related]
18. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Ladetto M; Zallio F; Vallet S; Ricca I; Cuttica A; Caracciolo D; Corradini P; Astolfi M; Sametti S; Volpato F; Bondesan P; Vitolo U; Boccadoro M; Pileri A; Gianni AM; Tarella C Leukemia; 2001 Dec; 15(12):1941-9. PubMed ID: 11753616 [TBL] [Abstract][Full Text] [Related]
19. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Nguyen DT; Amess JA; Doughty H; Hendry L; Diamond LW Eur J Haematol; 1999 Feb; 62(2):76-82. PubMed ID: 10052709 [TBL] [Abstract][Full Text] [Related]
20. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]